ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1571822
Quantitative Evaluation of Dual-Channel Drug Supply Policy on Nationally Negotiated Anti-Tumor Drugs In Xuzhou: Based on Interrupted Time Series Analysis
Provisionally accepted
- 1Xuzhou Medical University, Xuzhou, China
- 2China University of Mining and Technology, Xuzhou, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In September 2021, the "dual-channel" supply policy for anti-tumor drugs had launched in China. This policy solved the problem of difficult and expensive access to antitumor drugs. It was also crucial to the development of pharmaceutical reform. Taking Xuzhou City as typical case, this study aims to measure the impacts of the dual-channel policy on indicators of availability, cost, and reimbursement ratio. We adopt the interrupted time series analysis method and selects data on anti-tumor drug payments from October 2020 to October 2022 in Xuzhou City. The results show that the cost of anti-tumor drugs has increased significantly, and the number of purchases and reimbursement ratio and other indicators have increased after September 2021. It is worth noting that the changes in urban and rural residents' health insurance are more significant than those of employees' health insurance, which indicates that the policy has greatly improved accessibility to anti-tumor drugs and reduced the financial burden of disease for ordinary residents.
Keywords: Quantitative evaluation, Dual-channel, Anti-tumor drugs, Nationally Negotiated Drugs, interrupted time-series analysis
Received: 07 Feb 2025; Accepted: 08 Aug 2025.
Copyright: © 2025 Qin, Xu, Li, Guan, 何, Zhou and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhaohui Qin, Xuzhou Medical University, Xuzhou, China
Yan Xu, Xuzhou Medical University, Xuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.